- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01269502
Prevention of Secondary Foot Ulcers in Patients With Diabetes Using Systematic Measuring of Skin Temperature.
Prevention of Secondary Foot Ulcers in Patients With Diabetes. Will People With Diabetes Who Have Had a Foot Ulcer be Able to Prevent Secondary Ulcers by Systematically Measuring Their Skin Temperature?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes mellitus is linked to late complications from kidneys, eyes, nerves, feet, and an increased risk of cardiovascular disease.
Approximately 170 000 people in Norway suffer from diabetes, and diabetic foot disease is one of the most common complications.
It is estimated that between 400 and 500 amputations are performed yearly in Norway, and most of the amputations are due to non-healing diabetic foot ulcers.
Efficient prevention in high-risk individuals includes follow-up in specialist foot clinics including training in self-care, adaptation of preventive footwear and insoles.
A randomised trial testing the use of skin temperature measurement in addition to routine foot care for preventing new foot ulcers showing a highly significant reduction in recurrent foot ulcers in the temperature measuring group, has previously been performed in USA (Lavery et al. Diabetes Care 2007;30:14).
This study is planned as an open, randomised pilot study of minimum 40 patients testing the feasibility of implementing the use of skin temperature measurement for prevention of recurrent diabetic foot ulcers in a specialist clinical setting in Norway.
If this is the case, we are planning a larger study to examine if these measurements can contribute to reducing the number of recurrent ulcers in clinical practice in Norway.
We are in addition using a cognitive motivational method to examine if this model can increase the use of the temperature measuring device.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway, 0407
- Oslo University Hospital Ullevål
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Previous neuropathic diabetic foot ulcer
Exclusion Criteria:
- Ankle/brachial index < 0.7. Osteomyelitis, active Charcot
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Skin temperature measurement
Regular measurement of skin temperature on feet for one year
|
Daily measurement of skin temperature on feet for one year
|
|
Active Comparator: Active control
Daily inspection of feet for one year
|
Inspection of feet daily for one year
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Recurrency of diabetic foot ulcer
Time Frame: One year
|
One year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bente K Kilhovd, Md, PhD, Oslo University Hospital Ulleval, Oslo, Norway
- Study Chair: Anita Skafjeld, Oslo University Hospital, Ullevål, Oslo, Norway
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6.2009.60
- 20 (Sophies Minde Ortopedi AS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Foot Ulcer, Diabetic
-
DEBx Medical B.V.Not yet recruitingDiabetic Foot Wounds | Diabetic Foot Ulcer (DFU) | Diabetic Foot Ulcer Treatment
-
StimLabsNot yet recruitingDiabetic Foot | Foot Ulcer | Ulcer Foot | Diabetic Foot Ulcer (DFU)
-
Applied Biologics, LLCSerena GroupRecruitingUlcer | Diabetic Foot Ulcer | Diabetic Foot Ulcers (DFU) | Foot Ulcer ChronicUnited States
-
PolarityTETemporarily not availableNeuropathic Diabetic Ulcer - Foot | Diabetic Foot Disease | DFU
-
Cairo UniversityNot yet recruitingDiabetic Foot UlcerEgypt
-
Omeza, LLCSygNola, LLCRecruitingDiabetic Foot UlcerUnited States
-
Universidad Autonoma de Nuevo LeonCompleted
-
Applied Biologics, LLCSerenaGroup, Inc.RecruitingDiabetic Foot | Foot Ulcer | Diabetic Foot Ulcer | Ulcer Foot | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | DFUUnited States
-
Başakşehir Çam & Sakura City HospitalRecruitingDiabetic Foot Infection | Diabetic Amputation Foot Wound | Diabetic Foot DiseaseTurkey (Türkiye)
-
Libyan Center for Biotechnology ResearchNot yet recruiting
Clinical Trials on "Temp Touch" Diabetica Solutions inc.
-
University National Heart HospitalCompletedAtrial Fibrillation | Arrythmia | Electric CountershockBulgaria
-
Fondazione Evidence per Attività e Ricerche Cardiovascolari...Completed
-
physIQ, Inc.National Cancer Institute (NCI); University of Illinois at Chicago; National...Completed
-
University Hospital HeidelbergZOLL Circulation, Inc., USAUnknownIschemic Stroke | Hypothermia | ThrombolysisGermany
-
Heidelberg UniversitySiemens Medical SolutionsCompletedBreast NeoplasmsGermany, United States, France, Japan, Netherlands, Portugal
-
University of EdinburghCompletedMyocardial InfarctionUnited Kingdom
-
Liz DarlingLondon Health Sciences Centre; Trillium Health Partners; Oak Valley HealthNot yet recruiting
-
Salome KristensenCompletedRheumatoid Arthritis | Psoriatic Arthritis | Axial SpondyloarthritisDenmark
-
University of California, BerkeleyCompletedCorneal Epithelial Permeability
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); AMAG Pharmaceuticals, Inc.TerminatedBrain NeoplasmsUnited States